Table 1.

Mean and maximum bladder pressure at baseline and at each optogenetic stimulation frequency for double-transgenic CRH-ChR2 mice and for double-transgenic CRH-ChR2 mice after CRHR1 antagonist administration

Optogenetic stimulation frequency	Mean bladder pressure during cycle (mean ± SEM; mmHg)	p value (vs baseline)	Mean bladder pressure during cycle (mean ± SEM; mmHg)	p value (vs baseline)
Double CRH-ChR2 mice (n = 15)a
Baseline	3.5 ± 0.5		13.5 ± 1.6
2 Hz	3.4 ± 0.4	0.82	14.2 ± 1.7	0.40
25 Hz	3.3 ± 0.4	0.73	13.3 ± 1.6	0.55
50 Hz	3.2 ± 0.3	0.68	12.9 ± 1.6	0.78
Double CRH-ChR2 mice after CRHR1 antagonist administration (n = 4)b
Baseline	3.0 ± 1.0		9.9 ± 2.8
2 Hz	2.9 ± 0.7	0.72	10.8 ± 2.8	0.47
25 Hz	2.3 ± 0.7	0.36	10.1 ± 2.9	0.72
50 Hz	2.4 ± 0.4	0.45	9.4 ± 2.4	0.47

^aFor CRH-ChR2 mice (n = 15, 8 male, 7 female), there were no statistically significant differences between mean bladder pressure during each voiding cycle at baseline and at each optogenetic stimulation frequency. Similarly, there were no significant differences between the maximum bladder pressure reached during each cycle at baseline compared with at each optogenetic stimulation frequency.

^bFor CRH-ChR2 mice after administration of CRHR1 antagonist (n = 4, 2 male, 2 female), there were no statistically significant differences between mean bladder pressure during each voiding cycle at baseline and at each optogenetic stimulation frequency. Similarly, there were no significant differences between the maximum bladder pressure reached during each cycle at baseline compared with at each optogenetic stimulation frequency.